Etiopathogenesis and diagnostics of progressive multifocal leukoencephalopathy in patients treated with natalizumab

Česká verzia

Authors: P. Štourač ¹; J. Bednářová ²; Z. Pavelek ³
Authors place of work: Neurologická klinika LF MU a FN Brno ¹; Oddělení klinické mikrobiologie, FN Brno ²; Neurologická klinika LF UK, a FN Hradec Králové ³
Published in the journal: Cesk Slov Neurol N 2021; 84/117(2): 135-138
Category: Review Article
doi: https://doi.org/10.48095/cccsnn2021135

Summary

Etiologickým agens progresivní multifokální leukoencefalopatie (PML) je polyomavirus JCV (John Cunnigham virus). PML se vyskytuje u imunosuprimovaných pacientů vč. pacientů s RS léčených imunomodulačními léky. Aktivace JCV v nervovém systému a rozvoj PML je výsledkem dysregulace zahrnující genetické a imunitní buněčné mechanizmy. Z klinického pohledu je při léčbě natalizumabem přínosem vypracování léčebného algoritmu zohledňujícího míru rizika PML s ohledem na délku léčby, předchozí užívání imunosupresiv a hodnotu protilátkového indexu JCV. Současně s využitím MR lze diagnózu PML stanovit v preklinické fázi onemocnění a zlepšit prognózu onemocnění.

Keywords:

etiopathogenesis – progressive multifocal leukoencephalopathy – natalizumab

Zdroje

1. Padgett BL, Walker DL, ZuRhein GM et al. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971; 1(7712): 1257–1260. doi: 10.1016/ s0140-6736(71)91777-6.

2. Åström KE, Mancall EL, Richardson EP Jr et al. Progressive multifocal leuko-encephalopathy, a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin’s disease. Brain 1958; 81(1): 93–111. doi: 10.1093/ brain/ 81.1.93.

3. Knowles WA, Pipkin P, Andrews N et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003; 71(1): 115–123. doi: 10.1002/ jmv.10450.

4. Brew BJ, Davis NW, Cinque P et al. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol 2010; 6(12): 667–679. doi: 10.1038/ nrneurol.2010.164.

5. Pietropaolo V, Videtta M, Fioriti D et al. Rearrangement patterns of JC virus noncoding control region from different biological samples. J Neurovirol 2003; 9(6): 603–611. doi: 10.1080/ 13550280390246507.

6. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010; 61: 35–47. doi: 10.1146/ annurev.med.080708.082655.

7. Monaco MC, Jensen PN, Hou J et al. Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection. J Virol 1998; 72(12): 9918–9923. doi: 10.1128/ JVI.72.12.9918-9923.1998.

8. Chapagain ML, Nerurkar VR. Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier. J Infect Dis 2010; 202(2): 184–191. doi: 10.1086/ 653823.

9. Jiang M, Abend JR, Johnson SF et al. The role of polyomaviruses in human disease. Virology 2009; 384(2): 266–273. doi: 10.1016/ j.virol.2008.09.027.

10. Lima MA, Marzocchetti A, Autissier P et al. Frequency and phenotype of JC virus – specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy. J Virol 2007; 81(7): 3361–3368. doi: 10.1128/ JVI.01809-06.

11. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9(4): 425–437. doi: 10.1016/ S1474-4422(10)70040-5.

12. Manley K, O’Hara BA, Gee GV et al. NFAT4 is required for JC virus infection of glial cells. J Virol 2006; 80(24): 12079–12085. doi: 10.1128/ JVI.01456-06.

13. Wollebo HS, Safak M, Del Valle L et.al. Role for tumor necrosis factor-alfa in JC virus reactivation and progressive multifocal leukoencephalopathy. J Neuroimmunol 2011; 233(1–2): 46–53. doi: 10.1016/ j.jneuroim.2010.11.013.

14. Perez-Liz G, Del Valle L, Gentilella A et al. Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol 2008; 64(4): 379–387. doi: 10.1002/ ana.21443.

15. Lindberg RL, Achtnichts L, Hoffmann F et al. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 2008; 194(1–2): 153–164. doi: 10.1016/ j.jneuroim.2007.11.007.

16. Gorelik L, Reid C, Testa M et al. Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. J Infect Dis 2011; 204(1): 103–114. doi: 10.1093/ infdis/ jir198.

17. Marshall LJ, Dunham L, Major EO. Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter/ enhancer of JC virus and support viral activity. J Gen Virol 2010; 91(12): 3042–3052. doi: 10.1099/ vir.0.023184-0.

18. Tan IL, McArthur JC, Clifford DB et al. Immune reconstitution inflammatory syndrome in natalizumab – associated PML. Neurology 2011; 77(11): 1061–1067. doi: 10.1212/ WNL.0b013e31822e55e7.

19. Plavina T, Bergman M, Njenga M et al. Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma. J Clin Virol 2012; 53: 65–71. doi: 10.1016/ j.jcv.2011.10.003.

20. Lee P, Plavina T, Castro A et al. A second-generation ELISA (Stratify JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 2013; 57(2): 141–146. doi: 10.1016/ j.jcv.2013.02.002.

21. Cinque P, Scarpellini P, Vao L et al. Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction AIDS 1997; 11(1): 1–17. doi: 10.1097/ 00002030-199701000-00003.

22. Marzocchetti A, Di Giambenedetto S, Cingolani A et al. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol 2005; 43(8): 4175–4177. doi: 10.1128/ JCM.43.8.4175-4177.2005.

23. Polman CH, O’Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354(9): 899–910. doi: 10.1056/ NEJMoa044397.

24. Global Natalizumab (Tysabri) Postmarketing PML Update. Updated March 2020, Biogen Tysabri (Natalizumab). [online]. Available from URL: https:/ / www.tysabrihcp.com/ .

25. Vaněčková M, Martinková A,Tupý R et al. Spektrum MR nálezů progresivní multifokální leukoencefalopatie u kohorty pacientů s roztroušenou sklerózou v ČR. Cesk Slov Neurol N 2019; 82/ 115(4): 381–390. doi: 10.14735/ amcsnn2019381.

26. Giovannoni G, Kappos L, Berger J et al. Incidence of natalizumab associated progressive multifocal leukoencephalopathy and Its relationship with the pattern of natalizumab exposure over time. ECTRIMS Online Library. Giovannoni G. 10/ 10/ 18; 228448; P604.

27. Petržalka M, Meluzínová E, Mojžíšová H et al. Efektivita prodlouženého dávkovacího intervalu natalizumabu u pacientů s roztroušenou sklerózou. Cesk Slov Neurol N 2020; 83/ 116(1): 79–83. doi: 10.14735/ amcsnn202079.